MediWound (MDWD) Stock: Buy, Sell, or Hold?
MDWD - MediWound Ltd.
$12.00
-0.18 (-1.48%)
▼
5d:
+1.27%
30d:
-13.23%
90d:
-16.96%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 19, 2026
25d
Get Alerted When MDWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MDWD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: MDWD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: MDWD is currently trading at $12.00, which is considered oversold relative to its 30-day fair value range of $12.30 to $13.70.
Technical Outlook: Technically, MDWD is in a strong downtrend. The price is currently testing key support at $11.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MDWD scores 83/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.67 (+155.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDWD is in a strong downtrend. The price is currently testing key support at $11.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MDWD scores 83/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.67 (+155.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$12.30 -
$13.70
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (83/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 155.6% below Wall St target ($30.67)
- BULLISH: Bottoming setup score 83/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$12.30 -
$13.70
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.66
(5.5%)
Support & Resistance Levels
Support Level
$11.84
Resistance Level
$12.90
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.24
Wall Street Target
$30.67
(+155.6%)
Revenue Growth (YoY)
-45.8%
Profit Margin
-170.1%
Share & Embed Analysis
Last updated: October 24, 2026 4:12 AM ET
Data refreshes hourly during market hours. Next update: 5:12 AM
Data refreshes hourly during market hours. Next update: 5:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
